X4 Pharmaceuticals (NASDAQ:XFOR) Issues Earnings Results

X4 Pharmaceuticals (NASDAQ:XFOR) announced its quarterly earnings results on Thursday. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.05, Zacks reports. The firm had revenue of $8.81 million during the quarter, compared to analysts’ expectations of $2.42 million. X4 Pharmaceuticals had a negative net margin of 1,106.30% and a negative return on equity of 94.90%.

X4 Pharmaceuticals Stock Up 0.5%

Shares of NASDAQ XFOR opened at $4.17 on Friday. X4 Pharmaceuticals has a 52 week low of $1.35 and a 52 week high of $4.83. The business has a 50-day simple moving average of $4.02 and a two-hundred day simple moving average of $3.94. The company has a quick ratio of 9.98, a current ratio of 10.18 and a debt-to-equity ratio of 0.45. The company has a market cap of $393.31 million, a P/E ratio of -0.92 and a beta of 0.37.

Insider Buying and Selling at X4 Pharmaceuticals

In related news, CFO David Kirske sold 8,543 shares of the company’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $4.26, for a total transaction of $36,393.18. Following the sale, the chief financial officer owned 167,750 shares of the company’s stock, valued at approximately $714,615. This represents a 4.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 1.13% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On X4 Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Squarepoint Ops LLC bought a new position in shares of X4 Pharmaceuticals during the 4th quarter valued at $50,000. Two Sigma Investments LP purchased a new stake in X4 Pharmaceuticals during the third quarter valued at about $47,000. Stifel Financial Corp purchased a new stake in X4 Pharmaceuticals during the fourth quarter valued at about $82,000. Virtu Financial LLC bought a new position in shares of X4 Pharmaceuticals during the fourth quarter valued at about $90,000. Finally, Man Group plc bought a new position in shares of X4 Pharmaceuticals during the fourth quarter valued at about $97,000. 72.03% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have recently weighed in on XFOR shares. Wells Fargo & Company assumed coverage on shares of X4 Pharmaceuticals in a research note on Friday, July 10th. They issued an “overweight” rating and a $11.00 price objective for the company. Leerink Partners started coverage on shares of X4 Pharmaceuticals in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $12.00 price target for the company. Finally, Weiss Ratings upgraded shares of X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 28th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $9.70.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.